New Zynamite® study adds to growing scientific portfolio for award-winning ingredient platform

摘要

PLT HEALTH SOLUTIONS, INC. have announced that a new study has been published that builds upon previous research showing 'experiential' benefits from the Zynamite ingredient platform. The new clinical trial, led by Professor David Kennedy, Director of the Brain, Performance and Nutrition Research Centre at Northumbria University and published in Nutrients, suggests a rapid and sustained boost for a wide range of cognitive functions after a single use of the ingredient. Zynamite is a patent-pending, proprietary Mangifera indica extract, standardized to ≥ 60% mangiferin, developed from sustainably harvested mango leaves. A self-affirmed GRAS ingredient, it has a portfolio of safety data and has been the subject of three pre-clinical and now seven clinical studies that demonstrate performance enhancement in both cognitive and physical performance. The ingredient is manufactured by Nektium Pharma, S.L. and marketed exclusively by PLT in the United States, Mexico, and Canada.